# Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals

> **NCT05786937** · PHASE1 · UNKNOWN · sponsor: **University of Sao Paulo General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- HIV Vaccine

## Interventions

- **BIOLOGICAL:** Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
- **BIOLOGICAL:** Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
- **OTHER:** Commercial ringer´s lactate solution

## Key facts

- **NCT ID:** NCT05786937
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05786937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05786937, "Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05786937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*